RTW Biotech Opportunities Ltd

RTW

GG00BKTRRM22

Closed End Funds

Delayed London S.E. Other stock markets 09:41:24 2024-12-03 am EST			5-day change	1st Jan Change
1.515 ^USD	+1.69%		+2.38%	+8.04%

Nov. 15	RTW Biotech notes drug approval in China for investee Corxel	AN
Nov. 04	RTW Biotech invests in inflammation treatment firm Evommune	AN

RTW Biotech Opportunities Ltd Reports Earnings Results for the Full Year Ended December 31, 2023

March 28, 2024 at 03:00 am EDT

RTW Biotech Opportunities Ltd reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 4.17 million compared to USD 2.17 million a year ago. Net income was USD 83.19 million compared to net loss of USD 39.44 million a year ago.

Latest news about RTW Biotech Opportunities Ltd

RTW Biotech notes drug approval in China for investee Corxel	Nov. 15	AN
RTW Biotech invests in inflammation treatment firm Evommune	Nov. 04	AN
RTW Biotech Opportunities announces launch of Kailera Therapeutics	Oct. 03	AN
RTW Biotech Opportunities Co-leads $400 Million Financing in Kailera Therapeutics	Oct. 03	MT
RTW Biotech invests in cancer treatment firm Aktis Oncology	Oct. 02	AN
RTW Biotech Opportunities Co-leads Financing Round for Aktis Oncology	Oct. 02	MT
RTW Biotech notes BioAge Labs' USD198 million initial public offering	Sep. 27	AN
RTW Biotech Opportunities to Halt Trading in GBP Quote on London Bourse	Sep. 26	MT
RTW Biotech half-year net asset value rises amid "challenging markets"	Sep. 13	AN
RTW Biotech Opportunities' H1 Net Investment Loss Widens	Sep. 13	MT
RTW Biotech Opportunities Ltd Reports Earnings Results for the Half Year Ended June 30, 2024	Sep. 12	CI
RTW Biotech Opportunities Invests in Jade Biosciences	Aug. 06	MT
RTW Biotech Opportunities Ltd Appoints Baroness Nicola Blackwood as an Independent, Non-Executive Director	Jul. 11	CI
RTW Biotech Opportunities Invests in Mirador Therapeutics, Santa Ana Bio	Jul. 02	MT
RTW Biotech touts private investing activity following new investments	Jul. 02	AN
RTW Biotech portfolio company to sell subsidiary for USD1.25 billion	Jun. 11	AN
RTW Biotech Opportunities Ltd commences an Equity Buyback Plan for 57,844,388 shares, representing 14.99% of its issued share capital, under the authorization approved on May 16, 2024.	May. 30	CI
RTW Biotech Opportunities Ltd?s Equity Buyback announced on July 20, 2023, has expired.	May. 16	CI
Future Metals celebrates state government grant	May. 15	AN
RTW Biotech Opportunities Invests in Lycia Therapeutics $106 Million Funding Round	May. 15	MT
RTW Biotech invests in cell and gene therapy company Obsidian	Apr. 05	AN
RTW Biotech Opportunities Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Franchise Brands sets targets, Cindrigo agrees loan	Feb. 20	AN
RTW Biotech Opportunities NAV increases 2.5% in January	Feb. 14	AN
RTW Biotech Opportunities Completes Arix Bioscience Acquisition	Feb. 13	MT

Chart RTW Biotech Opportunities Ltd

Duration

Period

RTW: Dynamic Chart

Company Profile

RTW Biotech Opportunities Ltd is a Guernsey-based focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. The Company invests in companies developing therapies and technologies that can significantly improve patients' lives. The Company seeks to achieve its investment objective by leveraging the Investment Manager's data driven pipeline of assets to invest in life sciences companies across various therapeutic categories and product types (including genetic medicines, biologics, traditional modalities, such as small molecule pharmaceuticals and antibodies, and medical devices). It intends to create a diversified portfolio of investments across a range of businesses, each pursuing the development of superior pharmacological or medical therapeutic assets to enhance the quality of life and/or extend patient life. The Company's portfolio is managed by RTW Investments, LP.

Employees

Sector

Closed End Funds

Calendar

2025-03-26 - Q4 2024 Earnings Release (Projected)

More about the company